| Company Name: | Tianyin Pharmaceutical Company, Incorporated | | Ticker Symbol: | TPI | | | WWW Address: | | | CEO: | Dr. Guoqing Jiang | | No. of Employees: | 972 | | Common Issue Type: | CS | | Business Description: | The Company is engaged in the development, manufacturing, marketing and sale of modernized traditional Chinese medicines and other pharmaceuticals in China.
|
| | | Industry Information: | DRUGS - Drug Manufacturers - Other [more like this] |
| | Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 3.41 |  0.1 | 2.9 | 4.29 | 3.35 | 3.41 | 3.34 | 144713 |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 79.8 | 23.4 | 0.00 | 0.32 | 0.03 | 8.5 | 2.9 | 4.37 - 0.68 |
| | KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 3.41 | $ | | PE Ratio - LTM | 8.5 | |
| Market Capitalisation | 79.7 | mil |
| Latest Shares Outstanding | 23.4 | mil |
| Earnings pS (EPS) | 0.32 | $ |
| Dividend pS (DPS) | 0.03 | ¢ |
| Dividend Yield | 2.9 | % |
| Dividend Payout Ratio | 8 | % |
| Revenue per Employee | 44,130 | $ |
| Effective Tax Rate | 17.2 | % |
| Float | 11.2 | mil |
| Float as % of Shares Outstanding | 48.0 | % |
| Foreign Sales | 0 | mil |
| Domestic Sales | 0 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 27.40 | % |
| Research & Devlopment (R&D) as % of Revenue | 1.00 | % |
| Gross Profit Margin | 52.0 | % |
| EBITDA Margin | 23.7 | % |
| Pre-Tax Profit Margin | 21.6 | % |
| Assets Turnover | 1.0 | % |
| Return on Assets (ROA) | 16.4 | % |
| Return on Equity (ROE) | 18.1 | % |
| Return on Capital Invested (ROCI) | 18.1 | % |
| Current Ratio | 5.8 | |
| Leverage Ratio (Assets/Equity) | 1.1 | |
| Interest Cover | 115.8 | |
| Total Debt/Equity (Gearing Ratio) | 0.03 | |
| LT Debt/Total Capital | 0.0 | % |
| Working Capital pS | 0.94 | $ |
| Cash pS | 0.61 | $ |
| Book-Value pS | 1.96 | $ |
| Tangible Book-Value pS | 1.35 | $ |
| Cash Flow pS | 0.39 | $ |
| Free Cash Flow pS | -0.02 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 1.74 | |
| Price/Tangible Book Ratio | 2.53 | |
| Price/Cash Flow | 8.8 | |
| Price/Free Cash Flow | -136.7 | |
| P/E as % of Industry Group | 39.0 | % |
| P/E as % of Sector Segment | 10.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Dividend Declared Date | 10/05/2009 |
| Dividend Ex-Date | 10/27/2009 |
| Dividend Record Date | 10/29/2009 |
| Dividend Pay Date | 12/09/2009 |
| Dividend Amount | 25 |
| Type of Payment | Cash Payment |
| Dividend Rate | 0.10 |
| Current Dividend Yield | 2.9 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 8.0 |
| 5-Y Average Payout Ratio | 0.0 |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | | | | | PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | -3.9 | 96 | 2,030 | 9,871 |
| 4 Weeks | 4.14 | 3.18 | 3.93 | -13.2 | 86 | 2,514 | 50,288 |
| 13 Weeks | 4.37 | 3.18 | 3.27 | 4.3 | 98 | 3,397 | 217,429 |
| 26 Weeks | 4.37 | 2.06 | 2.15 | 58.6 | 129 | 2,762 | 350,785 |
| 52 Weeks | 4.37 | 0.68 | 1.65 | 106.7 | 151 | 1,486 | 373,077 |
| YTD | 4.37 | 0.68 | - | 162.3 | 217 | 1,653 | 371,921 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 3.37 | 3.49 | 3.73 | 3.09 | 2.64 | 0.00 | 0.00 |
| | | | GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 0.00 | 0.0 | 2189.09 |
| Income | 0.00 | 0.0 | 0.00 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | 0.00 | NA | 0.00 |
| R&D | 0.00 | NA | 0.00 |
| Normalized Inc. | 0.00 | NA | 0.00 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | 40.2 | 40.2 | 28.2 |
| Earnings % | 22.2 | 22.2 | 32.4 |
| EPS % | 14.3 | 14.3 | 3.2 |
| EPS $ | 0.01 | 0.01 | 0.01 |
| | | | SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 42.50 |
| Current Ratio | 5.4 |
| Quick Ratio (Acid Test) | 4.2 |
| Liquidity Ratio (Cash) | 2.82 |
| Receivables Turnover | 7.8 |
| Average Collection Period | 46 |
| Working Capital/Equity | 47.1 |
| Working Capital pS | 1.08 |
| Cash-Flow pS | 0.48 |
| Free Cash-Flow pS | 0.02 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 13.26 |
| Financial Leverage Ratio (Assets/Equity) | 1.1 |
| Debt Ratio | 9.7 |
| Total Debt/Equity (Gearing Ratio) | 0.03 |
| LT Debt/Equity | 0.00 |
| LT Debt/Capital Invested | 0.0 |
| LT Debt/Total Liabilities | 0.0 |
| Interest Cover | 100.4 |
| Interest/Capital Invested | 0.23 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 1.28 |
| Tobin's Q Ratio | 1.76 |
| Current P/E Ratio - LTM | 8.50 |
| Enterprise Value (EV)/EBITDA | 6.90 |
| Enterprise Value (EV)/Free Cash Flow | 262.50 |
| Dividend Yield | 2.9 |
| Price/Tangible Book Ratio - LTM | 2.53 |
| Price/Book Ratio - LTM | 1.74 |
| Price/Cash Flow Ratio | 8.8 |
| Price/Free Cash Flow Ratio - LTM | -136.7 |
| Price/Sales Ratio | 1.71 |
| P/E Ratio (1 month ago) - LTM | 10.0 |
| P/E Ratio (26 weeks ago) - LTM | 6.3 |
| P/E Ratio (52 weeks ago) - LTM | 10.3 |
| 5-Y High P/E Ratio | 0.0 |
| 5-Y Low P/E Ratio | 0.0 |
| 5-Y Average P/E Ratio | 0.0 |
| Current P/E Ratio as % of 5-Y Average P/E | 0 |
| P/E as % of Industry Group | 39.0 |
| P/E as % of Sector Segment | 10.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 8.5 |
| PER SHARE FIGURES |
| LT Debt pS | 0.00 |
| Current Liabilities pS | 0.24 |
| Tangible Book Value pS - LTM | 1.35 |
| Book Value pS - LTM | 1.96 |
| Capital Invested pS | 1.75 |
| Cash pS - LTM | 0.61 |
| Cash Flow pS - LTM | 0.39 |
| Free Cash Flow pS - LTM | -0.02 |
| Earnings pS (EPS) | 0.32 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | 0.98 |
| Free Cash Flow Margin 5YEAR AVG | -108.35 |
| Net Profit Margin | 18.4 |
| Net Profit Margin - 5YEAR AVRG. | 0.0 |
| Equity Productivity | 1.05 |
| Return on Equity (ROE) | 19.3 |
| Return on Equity (ROE) - 5YEAR AVRG. | 0.0 |
| Capital Invested Productivity | 1.05 |
| Return on Capital Invested (ROCI) | 19.3 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | 0.0 |
| Assets Productivity | 1.00 |
| Return on Assets (ROA) | 17.4 |
| Return on Assets (ROA) - 5YEAR AVRG. | 0.0 |
| Gross Profit Margin | 52.0 |
| Gross Profit Margin - 5YEAR AVRG. | 0.0 |
| EBITDA Margin - LTM | 23.7 |
| EBIT Margin - LTM | 21.8 |
| Pre-Tax Profit Margin | 22.3 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 0.0 |
| Effective Tax Rate | 17.2 |
| Effective Tax Rate - 5YEAR AVRG. | 8.6 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 116 |
| Revenue per Employee | 44,130 |
| Net Income per Employee | 8,136 |
| Average Collection Period | 52 |
| Receivables Turnover | 7.8 |
| Day's Inventory Turnover Ratio | 64 |
| Inventory Turnover | 5.7 |
| Inventory/Sales | 8.9 |
| Accounts Payble/Sales | 2.76 |
| Assets/Revenue | 1.00 |
| Net Working Capital Turnover | 2.23 |
| Fixed Assets Turnover | 1.98 |
| Total Assets Turnover | 1.0 |
| Revenue per $ Cash | 3.47 |
| Revenue per $ Plant | 4.45 |
| Revenue per $ Common Equity | 1.05 |
| Revenue per $ Capital Invested | 1.05 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 26.4 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 0.0 |
| Research & Devlopment (R&D) as % of Revenue | 0.8 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 0.8 |
|
|  
| | |  |  | |
| |